NCT06461689Completed
Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer
Comparison of Changes in Tumor Burden (Toral Tumor Volume [TMTV] and Total Lesion Activity [TLA]) in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in the Monitoring of Metastatic Castration-resistant Prostate Cancer Treated With 177Lutetium-PSMA-617
Source: ClinicalTrials.gov · Last updated 25 Jun 2026
Brief summary (registry, in English)
To demonstrate the prognostic value of using post-therapy 177Lu-PSMA SPECT/CT versus 68Ga-PSMA-11 PET/CT in mCPRC patients progressing despite chemotherapy and treated with 177Lu-PSMA.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 80 (actual)
- First submitted
- 5 Jun 2024
- Start date
- 31 Dec 2024
- Primary completion date
- 1 Feb 2025
- Lead sponsor
- Central Hospital, Nancy, France
- Diseases
- Prostate cancer
- NCT number
- NCT06461689
What you commit to
- Study type: Observational
- Participants enrolled: 80
- From 31 Dec 2024 to the primary completion date, 1 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- no social security
- no acceptation to participating in retrospective study
Who the study is looking for
- patient who received a dose of 177lu-PSMA
- patient who had imaging by 68Ga-PSMA
- patient treated in Nancy hospital for its cancer prostate
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHRU de Nancy Coordinator of this site? Confirm its status | Vandœuvre-lès-Nancy | France | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.